Jim Cramer reviewed Hinge Health, Inc. (NYSE:HNGE) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. A caller asked what Cramer thinks of the stock, and he said: When we did a profile of it, I said you should buy it between $30 and $40. It looked good. I reiterate that this is a very good healthcare company… This is actually a really good time to buy it. It’s a very recession-proof stock, too, so I think you got a good one. Photo by Joshua Mayo on Unsplash ...

Hims & Hers (HIMS) has taken a beating, with the stock down roughly 70% from its $70 peak and now trading below $21 per share. But the story's changing. After the company's Novo Nordisk (NVO) deal and the end of the FDA shortage, Hims is shifting to a broader mix of branded, FDA-approved GLP-1s while pulling back from compounded supply. This is a shift in how the business operates. The question now is whether HIMS can build a profitable, durable model. In simple terms, Hims & Hers is an online health ...

Greensboro, NC, March 26, 2026 (GLOBE NEWSWIRE) -- Global Technologies, LTD (OTC: GTLL) is pleased to announce the successful completion of a comprehensive two-year independent audit, along with the filing of its most recent quarterly reports under the supervision of its PCAOB-registered auditing firm. This process included the audit and restatement of the Company’s 2024 financial statements, as well as the completion and filing of its Quarterly Reports for the periods ended September 30, 2025 and December ...

Key Takeaways HIMS and Doximity reflect two distinct digital health models across consumer and provider platforms.DOCS benefits from a scaled physician network and diversified tools across marketing, hiring and workflows.HIMS drives growth via subscriptions, telehealth integration and expansion into broader care categories.Digital healthcare continues to evolve across both direct-to-consumer and professional-focused platforms, with Hims & Hers Health, Inc. (HIMS) and Doximity, Inc. (DOCS) representing two d ...

CIMG Inc. Reports Q1 Financial Results Accessibility StatementSkip NavigationHONG KONG, March 25, 2026 /PRNewswire/ -- CIMG Inc. ("CIMG" or the "Company") (Nasdaq: IMG), a business group specializing in digital health and sales development, which utilizes technologies and marketing networks to enhance its business partners' sales growth and commercial value, today announced that it has reported its financial results for the three months ended December 31, 2025, which shows that the Company achieved signific ...

AIML Subsidiary NeuralCloud Enters Research Services Agreement with Baker Heart and Diabetes Institute to Support AI-Driven ECG Analysis ELEMENT-- Dr. Kegan Moneghetti commented, "High-quality ECG signal processing is essential when studying subtle autonomic and heart rate variability differences. NeuralCloud's MaxYieldâ"¢ platform provides a structured framework for extracting ECG metrics from existing recordings, with potential applications in cardiovascular research." TORONTO, ON / ACCESS Newswire/ March ...

The agreement includes approximately 330,000 Medicare Advantage members and more than 1.7 million commercial members in California, significantly expanding Rocket Doctor’s in-network reach across the state.Eligible members gain access to Rocket Doctor’s network of board-certified physicians, delivering primary care, chronic disease management, preventive services, and coordinated follow-up through its digital health platform and marketplace.The agreement builds on Rocket Doctor’s January 27, 2026 announceme ...

Key Takeaways HIMS operates a consumer-first platform, integrating telehealth, prescriptions and pharmacy fulfillment.HIMS expands in diagnostics with Labs and early cancer detection, plus specialty care like GLP-1 therapies.Hims & Hers scales globally via acquisitions like Eucalyptus and expansion into Canada and Europe.Renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS) is fundamentally built as a consumer-first digital health platform that uses technology to reconfigure how care is acc ...

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the company’s control, including the risks described from time to time in its SEC filings. The company’s results may differ materially from those projections. These statements involve material risks and uncertainties that could cause actual results or events to differ materially. Accordingly, you should not place undue reliance on these statements. I encourage you to review the company’s filings with the SEC ...

DarioHealth (NasdaqCM:DRIO) Q4 2025 Earnings call March 19, 2026 08:30 AM ET Speaker3Good morning, ladies and gentlemen, and welcome to the DarioHealth fourth quarter and year-end 2025 results conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, March 19, 2026. I would now li ...